Notably, a soluble AXL decoy receptor-Fc fusion molecule, that has been affinity matured for enhanced GAS6 binding over the wildtype soluble AXL (80-fold enrichment), has generated specific and potent antitumor responses as a single agent therapy in preclinical models of cancer [96]. The gene discussed is GAS6; the disease is cancer.